Quick Answer
Protara Therapeutics, Inc. reported R&D Expense of $42.63 million for fiscal year 2025.
Protara Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $42.63M | +34.5% |
| 2024 | $31.70M | +26.9% |
| 2023 | $24.99M | +48.7% |
| 2022 | $16.81M | -20.3% |
| 2021 | $21.09M | +76.0% |
| 2020 | $11.98M | +209.0% |
| 2019 | $3.88M | -67.3% |
| 2018 | $11.85M | -45.4% |
| 2017 | $21.69M | +14.9% |
| 2016 | $18.87M | +52.4% |
| 2015 | $12.38M | +92.5% |
| 2014 | $6.43M | +61.0% |
| 2013 | $3.99M | -32.4% |
| 2012 | $5.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.59M | +18.8% | -10.9% |
| June 30, 2025 | $10.77M | +68.6% | +17.7% |
| March 31, 2025 | $9.15M | +18.1% | +13.4% |
| September 30, 2024 | $8.07M | +29.8% | +26.4% |
| June 30, 2024 | $6.39M | -11.9% | -17.6% |
| March 31, 2024 | $7.75M | +50.7% | +24.6% |
| September 30, 2023 | $6.22M | +79.4% | -14.2% |
| June 30, 2023 | $7.25M | +135.0% | +40.9% |
- Protara Therapeutics, Inc. showed an increase of +34.5% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Protara Therapeutics, Inc.’s r&d expense has grown by 621.7% (from $5.91 million to $42.63 million).
- The most recent figure is from Protara Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: